intravitreal injection of conbercept

PreclinicalProtein / enzyme

intravitreal injection of conbercept is one of 71 small molecule programs targeting Proliferative Diabetic Retinopathy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Proliferative Diabetic RetinopathyActive, not recruiting

Vascular DiseaseActive, not recruiting

Proliferative Diabetic RetinopathyPreclinical

Active, not recruiting

Vascular DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

66 competitors in Vascular Disease

#DrugCompanyPhaseTrials

Crestor

AstraZeneca

Approved

2 2

Repatha

Amgen

Approved

1 3

Precose

Bayer

Approved

1 4

Letairis

Andriol

1 6

Xarelto

WWim Janssens

Approved

1 7

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Approved

1 8

Zesly

MMezzion Pharma Co. Ltd

Approved

1 9

Donepezil Hydrochloride

Eisai

Approved

2 10

Ranexa

MMenarini International Operations Luxembourg SA

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Proliferative Diabetic Retinopathy1 trial

Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy

Unknown status·SSun Yat-sen University·N/A·NCT02911311·226 enrolled

Uveitic Macular Edema1 trial

Effects of Conbercept in Refractory Uveitic Macular Edema and VEGF

Terminated·PPeking Union Medical College Hospital·Phase 2/3·NCT04296838·5 enrolled

Vascular Disease1 trial

Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases

Unknown status·XXun Xu··NCT03128463·5,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for intravitreal injection of conbercept. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — intravitreal injection of conbercept compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for intravitreal injection of conbercept. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Preclinical[1]
Company: SSun Yat-sen University

intravitreal injection of conbercept

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Proliferative Diabetic Retinopathy1 trial

Uveitic Macular Edema1 trial

Vascular Disease1 trial

References

Drug Info

Quick Facts

Related News